{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"196-480-528-131-839","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"196-480-528-131-839","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11655,"type":"PATENT","title":"University of Freiburg - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":2803,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8321,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:uni* freiburg
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 2438
Search Applicants and Owners separately:uni* freiburg
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 2438
a) determining in a urine sample from the subject a level of miR-21 gene product, miR-125b gene product, miR-375 gene product, miR-451 gene product, or combinations thereof;
b) comparing the level of the miR-21 gene product in the urine sample to a control level of miR-21 gene product, comparing the level of the miR-125b gene product in the urine sample to a control level of miR-125b gene product, comparing the level of the miR-375 gene product in the urine sample to a control level of miR-375 gene product, and/or comparing the level of miR-451 gene product in the urine sample to a control level of miR-451 gene product; and
c) diagnosing whether the subject has breast cancer, wherein (i) a decrease in the level of miR-21 gene product in the urine sample, relative to the control level of miR-21 gene product, (ii) a decrease in the level of miR-125b gene product in the urine sample, relative to the control level of miR-125b gene product, (iii) a decrease in the level of miR-375 gene product in the urine sample, relative to the control level of miR-375 gene product, and/or (iv) a decrease in the level of miR-451 gene product in the urine sample, relative to the control level of miR-451 gene product, is indicative of the subject having breast cancer."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of any one of the preceding claims, comprising
a) determining in the urine sample from the subject a level of miR-21 gene product, miR-125b gene product, and miR-451 gene product,
b) comparing the level of the miR-21 gene product in the urine sample to a control level of miR-21 gene product, comparing the level of the miR-125b gene product in the urine sample to a control level of miR-125b gene product, and comparing the level of miR-451 gene product in the urine sample to a control level of miR-451 gene product; and
c) diagnosing whether the subject has breast cancer, wherein (i) a decrease in the level of miR-21 gene product in the urine sample, relative to the control level of miR-21 gene product, (ii) a decrease in the level of miR-125b gene product in the urine sample, relative to the control level of miR-125b gene product, and (iii) a decrease in the level of miR-451 gene product in the urine sample, relative to the control level of miR-451 gene product, is indicative of the subject having breast cancer."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 3 or 4, further comprising:
a) determining in the urine sample from the subject a level of miR-155 gene product,
b) comparing the level of the miR-155 gene product in the urine sample to a control level of miR-155 gene product, and
c) diagnosing whether the subject has breast cancer, wherein an increase in the level of miR-155 gene product in the urine sample, relative to the control level of miR-155 gene product, is indicative of the subject having breast cancer."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of any one of the preceding claims, wherein the control sample is a urine sample from one or more healthy individuals."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of any one of the preceding claims, wherein the subject is a female human."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of any one of the preceding claims, wherein the level of miR gene product(s) is measured by quantitative RT-PCR or by hybridisation using an oligonucleotide microarray."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of any one of the preceding claims, wherein the levels of miR-21 gene product, miR-125b gene product, and miR-451 gene product in the urine sample from the subject, relative to the respective control levels of the corrsponding gene products, are decreased by at least 25% to be indicative of breast cancer, and/or wherein the level of miR-155 gene product, in the urine sample from the subject, relative to the control level of miR-155 gene product, is increased by at least 25% to be indicative of breast cancer."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["A kit for the detection or diagnosis of breast cancer, comprising an oligonucleotide capable of hybridizing to a nucleic acid consisting of SEQ ID NO:1 or 2, an oligonucleotide capable of hybridizing to a nucleic acid consisting of SEQ ID NO:3, 4 or 9, and an oligonucleotide capable of hybridizing to a nucleic acid consisting of SEQ ID NO:5 or 6."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The kit of claim 10, further comprising an oligonucleotide capable of hybridizing to a nucleic acid consisting of SEQ ID NO:7 or 8."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The use of an oligonucleotide capable of hybridizing to a nucleic acid consisting of SEQ ID NO:1 or 2, of an oligonucleotide capable of hybridizing to a nucleic acid consisting of SEQ ID NO:3, 4 or 9, and/or of an oligonucleotide capable of hybridizing to a nucleic acid consisting of SEQ ID NO:5 or 6 for the diagnosis of breast cancer, said use comprising contacting the oligonucleotide(s) with a urine sample."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The use of claim 12, further comprising contacting an oligonucleotide capable of hybridizing to a nucleic acid consisting of SEQ ID NO:7 or 8 with said urine sample."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The kit or use of any one of claims 10 to 13, wherein said oligonucleotide capable of hybridizing to a nucleic acid consisting of SEQ ID NO:1 or 2 is perfectly complementary to SEQ ID NO:2, the oligonucleotide capable of hybridizing to a nucleic acid consisting of SEQ ID NO:3, 4 or 9 is perfectly complementary to SEQ ID NO:4, and/or the oligonucleotide capable of hybridizing to a nucleic acid consisting of SEQ ID NO:5 or 6 is perfectly complementary to SEQ ID NO:6."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The kit or use of any one of claims 11, 13 or 14, wherein said oligonucleotide capable of hybridizing to a nucleic acid consisting of SEQ ID NO:7 or 8 is perfectly complementary to SEQ ID NO:8."],"number":15,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}